Company Symposia

7:00 8:00 9:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00
Tuesday, September 27, 2005
10:30 - 12:00
F-27-01  Novartis Pharma AG (Basel/CH) Symposium: Verteporfin in Combination with Triamcinolone in the Management of Neovascular AMD

Schmidt-Erfurth U. (Wien)

Pauleikhoff D. (Münster)
Augustin A. J. (Karlsruhe)
Bandello F. (Udine)

Venue: Hall 4/5


This program will provide an update on current and emerging treatment modalities for age-related macular degeneration, with a specific focus on combination treatment using photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide (TA). The rationale for use of verteporfin therapy as the cornerstone therapy in combination with drugs such as TA or anti-VEGF agents will be described, and results from investigations of combination treatment will be presented.


10:30 F-27-01.01 Welcome and Introduction
Schmidt-Erfurth U., Vienna, Austria

10:35 F-27-01.02 Focusing on patient needs in AMD Treatment
Pauleikhoff D. 
Department of Ophthalmology, St Franziskus Hospital, Muenster, Germany

10:50 F-27-01.03 Mechanism of Action of Verteporfin and Rationale for Combination Therapy
Schmidt-Erfurth U. 
University Clinic for Eye Medicine and Optometry, University of Vienna, Vienna, Austria

11:10 F-27-01.04 Verteporfin and Intravitreal Triamcinolone in Subfoveal Lesions
Augustin A. J. 
Department of Ophthalmology, Klinikum Karlsruhe, Karlsruhe, Germany

11:30 F-27-01.05 Future Directions in AMD Treatment
Bandello F. 
Department of Ophthalmology, University of Udine, Udine, Italy

11:50 Discussion